Volasertib is under clinical development by Oncoheroes Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Volasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Volasertib (BI 6727) is under development for the treatment of myelodysplastic syndrome, rhabdomyosarcoma, acute myeloid leukemia (AML) and solid tumors including leukemia, lymphoma. The drug candidate is administered as intravenous infusion. The drug targets polo-like kinase 1 (PLK-1). It is a new chemical entity (NCE).
It was also under development for the treatment of refractory anemia with excess blasts, chronic myelomonocytic leukemia (CMML), metastatic urothelial cancer, acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, acute lymphoblastic leukemia, relapsed and refractory cutaneous T-cell lymphoma, peripheral T-cell lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma and burkitt lymphoma.
Oncoheroes Biosciences overview
Oncoheroes Biosciences is a biotechnology company which discovers, develops and commercializes oncology drugs for the treatment of childhood and adolescent cancers. The company is investigating 2HIT, a drug used for the treatment of central nervous system malignant tumor and volasertib, a polo like kinase 1 (PLK1) inhibitor targeting rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma. It works in partnership with Xenopat, CDTI, Institute for bioengineering of California and other companies to develop its products. Oncoheroes Biosciences is headquartered in Brookline, Massachusetts, the US.
For a complete picture of Volasertib’s drug-specific PTSR and LoA scores, buy the report here.